von Willebrand factor and its cleaving protease ADAMTS13 balance in coronary artery vessels: Lessons learned from thrombotic thrombocytopenic purpura. A narrative review

Morici, Nuccia; Cantoni, Silvia; Panzeri, Francesco; Sacco, Alice; Rusconi, Chiara; Stucchi, Miriam; Oliva, Fabrizio; Cattaneo, Marco

doi:10.1016/j.thromres.2017.05.011

Cited by 6 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…vWF participates in platelet adhesion and aggregation in combination with platelet membrane glycoprotein b and collagen at vascular lesions and stabilizes factor VIII activity by functioning as a carrier. Concentration of plasma ADAMTS13 decreases when vWF level increases during acute formation process of coronary thrombosis [20,26,27]. A possible speculation of potential mechanism might be that A mutant causes expression reduction of ADAMTS13, thus vWF concentration increases, which promoted platelet adhesion and aggregation.…”

Section: Discussionmentioning

confidence: 99%

Susceptible gene polymorphism in patients with three-vessel coronary artery disease

Liu

Song

Jiang

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background: Data of susceptible gene polymorphisms related to progression of coronary atherosclerosis in patients with three-vessel disease (TVD) is limited in China. This case-control study aimed to analyze the differences of variant carrier frequencies between cases and controls, and to explain the possible genetic effects on the progression of TVD. Methods: A total of 8943 TVD patients were consecutively enrolled. Major adverse cardiac and cerebrovascular events (MACCE) included all-cause death, acute myocardial infarction, repeat revascularization, readmission and stroke. Patients with 1-year MACCE in this cohort were selected as MACCE group. Blood samples from MACCE group and non-CAD control groups were collected, and a deoxyribonucleic acid library was created. A total of 34 tag or hot single nucleotide polymorphisms (SNPs) in six genes including CDKN2B-AS1, ADAMTS7, ABO, ADAMTS13, IL-18, and PECAM1 were analyzed by a SNPscan™ multi-genotyping kit. Carrier frequencies of each SNP were compared between the two groups using dominant, recessive and codominant allele model, respectively. Multivariate logistic regression model was established. Results: Variant allele frequencies of rs10757274, rs1333042, rs1333049, rs4977574, rs9632884, rs1063192 and rs3217986 on CDKN2B-AS1 gene showed significant differences between the two groups in at least one allele model. Variant allele frequency of rs3217986 was not statistically significant after adjusting for the false discovery rate using Benjamini-Hochberg procedure (Q > 0.05). Variant allele frequencies of rs1333049, rs10757274, rs4977574 on CDKN2B-AS1 gene were significantly higher in MACCE group in all dominant, recessive and codominant models. Rs1055432 on ADAMTS13 and rs8176694 on ABO gene showed threshold significance between the two groups. After multivariable adjustment, G mutant homozygous rs9632884 (GG vs. GC + CC) (OR: 0.24; 95% CI: 0.09-0.65; P = 0.005) on CDKN2B-AS1 gene were independent protective factor of MACCE in recessive model. Conclusions:In patients with TVD in China, variant alleles on CDKN2B-AS1 gene may form part of the genetic basis of coronary atherosclerosis progression, promoting or suppressing ischemic events.

show abstract

Section: Discussionmentioning

confidence: 99%

Susceptible gene polymorphism in patients with three-vessel coronary artery disease

Liu

Song

Jiang

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…Cardiac involvement in acute episodes of iTTP is heterogeneous and underrecognized [ 10 , 18 ]. Cardiac arrest and myocardial infarction are the most common immediate causes of death in iTTP, and autopsy studies commonly show cardiac involvement [ 9 ].…”

Section: Cardiovascular Involvement In Acute Ittpmentioning

confidence: 99%

Cardiovascular Disease and Stroke in Immune TTP–Challenges and Opportunities

Sukumar,

Mazepa,

Chaturvedi

2023

JCM

View full text Add to dashboard Cite

Advances in the management of immune thrombotic thrombocytopenic purpura (iTTP) have dramatically improved outcomes of acute TTP episodes, and TTP is now treated as a chronic, relapsing disorder. It is now recognized that iTTP survivors are at high risk for vascular disease, with stroke and myocardial infarction occurring at younger ages than in the general population, and cardiovascular disease is the leading cause of premature death in this population. iTTP appears to have a phenotype of accelerated vascular aging with a particular predilection for cerebral circulation, and stroke is much more common than myocardial infarction. In addition to traditional cardiovascular risk factors, low ADAMTS13 activity during clinical remission may be a risk factor for some of these outcomes, such as stroke. Recent studies also suggest that Black patients, who are disproportionately affected by iTTP in the United States, are at higher risk of adverse cardiovascular outcomes, likely due to multifactorial reasons. Additional research is required to establish the risk factors and mechanisms underlying these complications in order to institute optimal screening strategies and identify interventions to improve outcomes.

show abstract

Does this patient with thrombotic thrombocytopenic purpura have a cardiac involvement?

2018

View full text Add to dashboard Cite

von Willebrand factor and its cleaving protease ADAMTS13 balance in coronary artery vessels: Lessons learned from thrombotic thrombocytopenic purpura. A narrative review

Cited by 6 publications

References 67 publications

Susceptible gene polymorphism in patients with three-vessel coronary artery disease

Susceptible gene polymorphism in patients with three-vessel coronary artery disease

Cardiovascular Disease and Stroke in Immune TTP–Challenges and Opportunities

Does this patient with thrombotic thrombocytopenic purpura have a cardiac involvement?

Contact Info

Product

Resources

About